BPO 0.00% 0.3¢ bioprospect limited

bpo still on track....holding up well, page-8

  1. 3,696 Posts.
    lightbulb Created with Sketch. 270
    I would have thought that BPO would be in danger of missing the revenue target (was it $5m by the end of Dec 2010?).
    And yes BPO kept the R&D in-house, but I think that is because they had a minimum spend they needed to undertake to keep the rights.

    But either way, in Feb the two companies agreed to move forward, so presumably all the DD was done at that stage by SLA regarding BPO meeting its obligations.

    But of course, as shareholders we are blind as to the true state of affairs.
 
watchlist Created with Sketch. Add BPO (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.